
Quraxia is a leading Contract Research Organization (CRO) specializing in ADC development, monoclonal antibodies, and genomic and proteomic profiling using MALDI-Mass Spectroscopy for lung, neck, throat, and pancreatic cancers. Our team of experienced scientists and researchers are experts in all aspects of these fields.
Quraxia is an emerging biotechnology company specializing in advanced oligonucleotide synthesis services for customers worldwide. Equipped with state-of-the-art technology, sophisticated equipment, and a team of highly experienced scientists, Quraxia delivers a comprehensive range of high-quality oligonucleotide synthesis solutions. These include research-grade oligos, GMP-grade oligos, modified oligonucleotides, and high-throughput DNA and RNA oligo synthesis services.
Oligonucleotides (oligos) are short, single-stranded DNA or RNA molecules with diverse applications in biochemistry, molecular diagnostics, genomics, and molecular biology research. Depending on the intended use, oligos can be customized with a variety of modifications. Examples include:
Phosphate group addition at the 5' or 3' ends for ligation or extension blocking.
Labeling with fluorophores, quenchers, or radionuclides for probe-based applications.
Reactive moieties like thiol or amino groups for covalent coupling with functional molecules such as enzymes.
Linkers and spacers for specific structural or functional requirements.
Dye-labeled and structural phosphoramiditesfor specialized applications.
Quraxia is equipped to handle custom synthesis of biomolecules and intermediates in both gram and kilogram scales, ensuring flexibility for diverse project needs. With a dedicated team of trained scientists, Quraxia takes pride in meeting client expectations and achieving project targets with precision and reliability.
Partner with Quraxia for cutting-edge oligonucleotide synthesis services tailored to your research and production requirements.